DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-9.26%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$321M
AUM Growth
+$321M
(-12%)
Cap. Flow
-$3.96M
Cap. Flow
% of AUM
-1.23%
Top 10 Holdings %
Top 10 Hldgs %
50.52%
Holding
83
New
10
Increased
22
Reduced
13
Closed
8
Top Buys
| 1 |
Cytokinetics
CYTK
|
$4.32M |
| 2 |
TSVT
2seventy bio
TSVT
|
$3.73M |
| 3 |
Axogen
AXGN
|
$3.02M |
| 4 |
Merus
MRUS
|
$2.36M |
| 5 |
Tandem Diabetes Care
TNDM
|
$2.3M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$24.1M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$8.48M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$5.93M |
| 4 |
Lyra Therapeutics
LYRA
|
$1.48M |
| 5 |
Revolution Medicines
RVMD
|
$1.08M |
Sector Composition
| 1 | Healthcare | 82.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $41.3M | 12.83% | 565,000 | – | – |
|
2
Stereotaxis
STXS
$261M
| $21.6M | 6.72% | 13,680,554 | – | – |
|
|
3
Cytokinetics
CYTK
$4.23B
| $14.1M | 4.39% | 479,538 +146,804 | +44% | +$4.32M |
|
4
IDEAYA Biosciences
IDYA
$2.15B
| $13.5M | 4.19% | 499,820 +20,000 | +4% | +$540K |
|
|
5
Revolution Medicines
RVMD
$7.1B
| $13.1M | 4.08% | 473,394 -38,891 | -8% | -$1.08M |
|
6
Ascendis Pharma
ASND
$11.8B
| $12.8M | 3.97% | 136,212 +1,000 | +0.7% | +$93.6K |
|
7
iShares Biotechnology ETF
IBB
$5.6B
| $12.5M | 3.9% | 102,500 | – | – |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $12.5M | 3.9% | 249,521 -2,000 | -0.8% | -$100K |
|
|
9
Merus
MRUS
$4.98B
| $11.4M | 3.56% | 484,870 +100,000 | +26% | +$2.36M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $9.58M | 2.98% | 280,538 | – | – |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $8.94M | 2.78% | 52,873 +10,700 | +25% | +$1.81M |
|
12
Neurocrine Biosciences
NBIX
$13.8B
| $8.28M | 2.58% | 73,615 -1,000 | -1% | -$113K |
|
13
Day One Biopharmaceuticals
DAWN
$769M
| $7.2M | 2.24% | 586,463 +79,363 | +16% | +$974K |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.66M | 2.07% | 458,373 +7,500 | +2% | +$109K |
|
15
DexCom
DXCM
$29.5B
| $6.3M | 1.96% | 67,552 | – | – |
|
16
KalVista Pharmaceuticals
KALV
$678M
| $5.83M | 1.81% | 605,532 -5,500 | -0.9% | -$53K |
|
|
TSVT
17
DELISTED
2seventy bio
TSVT
| $5.67M | 1.76% | 1,447,465 +951,049 | +192% | +$3.73M |
|
18
AtriCure
ATRC
$1.84B
| $5.5M | 1.71% | 125,529 | – | – |
|
|
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.31M | 1.65% | 231,748 +25,000 | +12% | +$573K |
|
20
Kura Oncology
KURA
$686M
| $5.02M | 1.56% | 550,784 +193,000 | +54% | +$1.76M |
|
|
21
Axogen
AXGN
$743M
| $4.68M | 1.46% | 935,894 +603,791 | +182% | +$3.02M |
|
22
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.62M | 1.44% | 652,000 +83,000 | +15% | +$588K |
|
|
23
Tandem Diabetes Care
TNDM
$845M
| $4.58M | 1.43% | 220,708 +110,708 | +101% | +$2.3M |
|
24
Nurix Therapeutics
NRIX
$714M
| $4.38M | 1.36% | 556,695 | – | – |
|
25
Alector
ALEC
$238M
| $4.08M | 1.27% | 628,938 -10,000 | -2% | -$64.8K |
|